Atrial natriuretic peptide induces shedding of endothelial glycocalyx in coronary vascular bed of guinea pig hearts.
Atrial natriuretic peptide (ANP) is reported to enhance vascular permeability in vivo. Our aim was to evaluate the impact of ANP on coronary extravasation of fluids and macromolecules and on the integrity of the endothelial glycocalyx. Isolated guinea pig hearts (n = 6/group) were perfused with Krebs-Henseleit buffer in a Langendorff mode. A 6% hydroxyethyl starch (HES) solution was infused into the coronary system for 20 min without (Control group) and simultaneously with (ANP group) ANP at 10(-9) M. In two further series, the glycocalyx was enzymatically degraded by means of heparinase (Hep) application (10 IU over 15 min), followed again by the infusion of HES in the absence (Hep group) and presence (ANP+Hep group) of ANP. Net fluid filtration, extravasation of HES, electron microscopic visualization of the glycocalyx, and quantification of shedding of syndecan-1, a component of the glycocalyx, were determined. An increase in fluid leak was observed in ANP, ANP+Hep, and Hep hearts [+29%, +31%, +14%, respectively; a decrease was observed in Control hearts (-13%)]. Similarly, an accelerated extravasation of colloid was observed in these three groups. Coronary release of syndecan-1 increased 9- to 18-fold during infusion of ANP. Electron microscopy revealed a dramatic degradation of the glycocalyx after ANP. These results indicate that the endothelial glycocalyx serves as a barrier to transmural exchange of fluid and colloid in the coronary vascular system. ANP causes rapid shedding of individual components of the glycocalyx and histologically detectable degradation. Thus the permeability-increasing effect of ANP may be at least partially related to changes in the integrity of the endothelial glycocalyx.
Bruegger
Dirk
D
Clinic for Anesthesiology, Ludwig-Maximilians-Univ., Marchioninistr. 15, D-81377 Munich, Germany.
Jacob
Matthias
M
Rehm
Markus
M
Loetsch
Michael
M
Welsch
Ulrich
U
Conzen
Peter
P
Becker
Bernhard Friedrich
BF
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D002199:Capillary Permeability / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects* / Q000648:ultrastructure; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000648:ultrastructure; D019276:Glycocalyx / Q000187:drug effects* / Q000648:ultrastructure; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects*; D006895:Hydroxyethyl Starch Derivatives; D066298:In Vitro Techniques; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism; D008854:Microscopy, Electron; D011509:Proteoglycans / Q000378:metabolism; D053667:Syndecans
D006895:Hydroxyethyl Starch Derivatives; D008562:Membrane Glycoproteins; D011509:Proteoglycans; D053667:Syndecans; D009320:Atrial Natriuretic Factor